Display options
Cite
Sedov V, Stuart RK. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol. 2017;8(6):185-195doi: 10.1177/2040620717703012.
Sedov, V., & Stuart, R. K. (2017). Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Therapeutic advances in hematology, 8(6), 185-195. https://doi.org/10.1177/2040620717703012
Sedov, Valeriy, and Stuart, Robert K. "Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape." Therapeutic advances in hematology vol. 8,6 (2017): 185-195. doi: https://doi.org/10.1177/2040620717703012
Sedov V, Stuart RK. Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape. Ther Adv Hematol. 2017 Jun;8(6):185-195. doi: 10.1177/2040620717703012. Epub 2017 Apr 21. PMID: 28567238; PMCID: PMC5424861.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Hematol. 2017 Jun;8(6):185-195. doi: 10.1177/2040620717703012. Epub 2017 Apr 21.

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.

Therapeutic advances in hematology

Valeriy Sedov, Robert K Stuart

Affiliations

  1. Medical University of South Carolina, 173 Ashley Avenue, Basic Science Building, Suite 102, Charleston, SC 29425-6350, USA.
  2. Medical University of South Carolina, Charleston, SC, USA.

PMID: 28567238 PMCID: PMC5424861 DOI: 10.1177/2040620717703012

Abstract

Treatment for acute myeloid leukemia (AML) generally consists of a combination of cytarabine and an anthracycline. Although induction therapy leads to complete remission (CR) for most patients, refractoriness to chemotherapy or relapse after initial response is associated with poor outcomes. The 1-year survival rates after first relapse have been reported at 29%, declining to 11% at 5 years. Prognosis is particularly poor among older patients whose higher prevalence of unfavorable cytogenetics and high frequency of comorbidities diminish their ability to tolerate intensive chemotherapy. There is no standard of care for relapsed/refractory (R/R) AML, and no new therapies have shown consistently superior outcomes in this setting in over two decades. Vosaroxin is an anticancer quinolone derivative (AQD) that was evaluated in combination with cytarabine for the treatment of R/R AML in the randomized, double-blind, placebo-controlled, phase III VALOR study (

Keywords: AML; acute myelogenous leukemia; acute myeloid leukemia; vosaroxin

Conflict of interest statement

Conflict of interest statement: Robert Stuart has received research funding from and has served as a consultant to Sunesis Pharmaceuticals. Valeriy Sedov has no relevant conflicts of interest to discl

References

  1. Drug Metab Dispos. 2009 Mar;37(3):594-601 - PubMed
  2. Hematology Am Soc Hematol Educ Program. 2012;2012:43-8 - PubMed
  3. J Clin Oncol. 1991 Jul;9(7):1210-4 - PubMed
  4. Lancet Oncol. 2015 Sep;16(9):1025-36 - PubMed
  5. Blood. 2006 May 1;107(9):3481-5 - PubMed
  6. Blood. 2009 Nov 5;114(19):4027-33 - PubMed
  7. Baillieres Clin Haematol. 1996 Mar;9(1):147-59 - PubMed
  8. Blood. 1983 Jul;62(1):1-13 - PubMed
  9. Eur J Haematol. 2008 Feb;80(2):115-26 - PubMed
  10. J Clin Oncol. 2005 Mar 20;23(9):1969-78 - PubMed
  11. PLoS One. 2010 Apr 15;5(4):e10186 - PubMed
  12. Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8 - PubMed
  13. J Clin Oncol. 2012 Jul 10;30(20):2492-9 - PubMed
  14. Haematologica. 2015 Feb;100(2):231-7 - PubMed
  15. Blood. 2010 Jan 21;115(3):453-74 - PubMed
  16. Cancer. 2013 Aug 1;119(15):2720-7 - PubMed
  17. Br J Haematol. 2001 Jan;112(1):127-37 - PubMed
  18. Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65 - PubMed
  19. Blood. 2011 Mar 24;117(12):3294-301 - PubMed
  20. Eur J Haematol. 2003 Sep;71(3):155-62 - PubMed
  21. J Clin Oncol. 2014 Jun 20;32(18):1919-26 - PubMed
  22. Protein Cell. 2013 Oct;4(10 ):735-46 - PubMed
  23. J Clin Oncol. 2005 Jun 20;23(18):4110-6 - PubMed
  24. Am J Hematol. 1998 Jun;58(2):105-9 - PubMed
  25. J Clin Oncol. 2004 Mar 15;22(6):1078-86 - PubMed

Publication Types